|
Leukemia, Myelocytic, Acute
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutations are closely related to the development and progression of various human cancers, such as glioblastoma, sarcoma, and acute myeloid leukemia.
|
31836442 |
2020 |
|
Leukemia, Myelocytic, Acute
|
0.700 |
Biomarker
|
disease |
BEFREE |
Advances in the understanding of the complex mechanisms of AML leukemogenesis have led to the development and recent US Food and Drug Administration (FDA) approval of several targeted therapies: midostaurin and gilteritinib targeting activated FLT3, and ivosidenib and enasidenib targeting mutated IDH1/2.
|
31848884 |
2020 |
|
Leukemia, Myelocytic, Acute
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in isocitrate dehydrogenase 1 (IDH1) are found in 6% of AML patients.
|
31586149 |
2020 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
IDH2 mutations were associated with better outcomes compared with IDH wild-type gliomas (P < 0.05).
|
31833906 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
rLTL was measured by qPCR in a Swedish population-based glioma case-control cohort (421 cases and 671 controls). rLTL was related to glioma risk and health parameters associated with asthma and allergy, as well as molecular events in glioma including IDH1 mutation, 1p/19q co-deletion, and EGFR amplification.
|
30560391 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the isocitrate dehydrogenase-1 gene (IDH1) occur at high frequency in grade II-III gliomas (LGGs).
|
31240524 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
<sup>18</sup>F-DOPA uptake does not correlate with IDH mutation status and 1p/19q co-deletion in glioma.
|
30607877 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Recent DNA methylation analyses revealed a small group of IDH mutant diffuse gliomas exhibiting decreased DNA hypermethylation resulting in substantial unfavorable prognosis comparable to glioblastoma.
|
30937703 |
2019 |
|
Glioma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the relationship between SWI features and glioma grades, and the expression of key molecular markers isocitrate dehydrogenase 1 (IDH1), O-6-methylguanine-DNA methyltransferase (MGMT), and 1p19q.
|
31745161 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Additionally, 5-aza enhances the therapeutic effect of the DNA damaging agent TMZ in both subcutaneous and orthotopic PDX models of IDH1 R132H mutant glioma.
|
30184215 |
2019 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
An analysis of 2589 patient samples showed that CLEC5A expression is higher in (1) glioblastoma than in lower-grade glioma and nontumor tissue, (2) in the mesenchymal subtype than in other subtypes, and (3) in IDH1-wild type glioblastoma than in IDH1-mutated glioblastoma.
|
31591460 |
2019 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
For instance, mutations in the <i>isocitrate dehydrogenase 1 (IDH1)</i> gene, which occurs in a subgroup of glioma, correlate with risk of VTE, with low incidence in patients with presence of an <i>IDH1</i> mutation compared with those with <i>IDH1</i> wild-type status.
|
31041803 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In this study, using our mouse model and primary patient-derived glioma cultures with IDH1 mutations, we investigated the function of IDH1<sup>R132H</sup> in the context of TP53 and ATRX loss.
|
30760578 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
There is variability in survival within IDH mutant gliomas determined by chromosomal events.
|
31134296 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Using the combination, the diagnostic sensitivity and specificity for IDH1 mutated gliomas were 93.3% and 88.9%, respectively.
|
30414094 |
2019 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Increasing researchers have been involved in the study of glioma cell metabolism reprogramming since the significance of IDH1 was confirmed in glioma.
|
30978442 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
MATH values were increased in patients with glioma with the wild-type isocitrate dehydrogenase (NADP<sup>(+)</sup>) (IDH)1/2 (IDH-wt) gene (P=0.001) and glioblastoma (GBM; P=0.001).
|
31788085 |
2019 |
|
Glioma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Podoplanin Expression and IDH-Wildtype Status Predict Venous Thromboembolism in Patients with High-Grade Gliomas in the Early Postoperative Period.
|
31100523 |
2019 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Fifty-seven LGG patients with IDH1(+) (n = 36 with 19 ATRX(-) and 17 ATRX(+) patients) and IDH1(-) (n = 21).
|
30194745 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
One hundred and two individuals with IDH1/2 mutant or 1p/19q co-deleted glioma were genotyped and linked to the UPDB.
|
30823903 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis incorporating tumor status based on the presence of <i>IDH</i> mutations, <i>TERT</i> promoter mutations, and 1p/19q codeletion showed that in lower-grade gliomas, high NLR predicted poorer survival for the triple-negative, IDH mutation only, TERT mutation only, and IDH and TERT mutation groups.
|
31444316 |
2019 |
|
Glioma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In contrast, IDH1 wt expression is upregulated in all glioma grades (concentration >0.1) compared to control brain tissue (0.007 ± 0.0016).
|
30943868 |
2019 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
IDH Inhibitors Target Common Glioma Mutation.
|
31217295 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We hypothesize that the primary cell pool isolated from LGG tumor contains a heterogeneous population consisting tumor cells at various stages of tumor progression including cells with early genetic lesions if any prior to acquisition of IDH1 mutation.
|
30460631 |
2019 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Therefore, MET uptake for glioma grading was more consistent for IDH1-wildtype tumours than for IDH1-mutant tumours.
|
31102001 |
2019 |